Testosterone level and mortality in elderly men with systolic chronic heart failure

Asian Journal of Andrology

Volumn 13, Issue 5, 2011, Pages 759-763

  Wu, Hai Yun ^a   Wang, Xiao Fei ^b   Wang, Jun Hua ^c   Li, Jiang Yuan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 306 HOSPITAL OF PLA   (China)

^c AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

free testosterone; heart failure; prognosis; total testosterone

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AGED; AGING; ARTICLE; CHRONIC DISEASE; GERIATRIC PATIENT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONE BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SERUM; SURVIVAL RATE; SYSTOLIC HEART FAILURE; TESTOSTERONE BLOOD LEVEL;

AGED; ANDROGENS; CHRONIC DISEASE; COHORT STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TESTOSTERONE;

EID: 80052472876     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.26     Document Type: Article

References (26)

1. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 2007; 115: 1563-70.
2. Gu DF, Huang GY, He J. Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population. Chin J Cardiol 2003; 31: 3-6.
3. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-34.
4. Moriyama Y, Yasue H, Yoshimura M, Mizuno Y, Nishiyama K et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 2000; 85: 1834-40.
5. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003; 87: 179-83.
6. Sacca L. Heart failure as a multiple hormone deficiency syndrome. Circ Heart Fail 2009; 2: 151-6.
7. Anker SD, Clark AL, Kemp M, Salsbury C, Teixeira MM et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30: 997-1001.
8. Iellamo F, Rosano G, Volterrani M. Testosterone deficiency and exercise intolerance in heart failure: treatment implications. Curr Heart Fail Rep 2010; 7: 59-65.
9. Malkin CJ, Channer KS, Jones TH. Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes 2010; 17: 262-8.
10. Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol1999; 83: 123-5.
11. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart 2004; 90: 446-7.
12. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57-64.
13. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-27.
14. Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010; 56: 1310-6.
15. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006; 114: 1829-37.
16. Gü der G, Frantz S, Bauersachs J, Ertl G, Angermann CE et al. Low circulating androgens and mortality risk in heart failure. Heart 2010; 96: 504-9.
17. Laghi F, Antonescu-Turcu A, Collins E, Segal J, Tobin DE et al. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am J Respir Crit Care Med 2005; 171: 728-33.
18. Li JY, Li XY, Li M, Zhang GK, Ma FL et al. Decline of serum levels of free testosterone in aging healthy Chinese men. Aging Male 2005; 8: 203-6.
19. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
21. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009; 30: 1-9.
22. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010.
23. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007; 167: 1252-60.
24. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002; 57: M76-99.
25. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009; 32: 587-98.
26. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405-13.